Background: To develop therapeutics for Alzheimer's disease, early detection of patients
Introduction
Alzheimer's disease (AD) represents one of the most demanding challenges in healthcare [1, 2] .
In light of demographic changes and failures in drug development [3] , early detection of the disease offers itself as one of the most promising approaches to improve patients' outcome on the mid-to long term. Therefore, circulating biomarkers are a major research topic towards the aim of early detection of AD.
The importance of minimal invasive molecular markers for AD is reflected by over 3,000 original manuscripts and reviews related to AD diagnosis from blood, serum or plasma samples published and indexed in PubMed. Among the promising approaches are plasma proteomic markers measured by mass spectrometry [4] , metabolic patterns [5] , gene expression profiles [6] , DNA methylation [7] , and small non-coding RNAs [8] . However, cohort sizes of such studies are often limited and larger validation cohorts frequently did not always match the original results [9] . One of the major challenges is the complexity of signatures that is often required to reach high specificity and sensitivity.
In previous research we performed deep sequencing to measure blood-borne Alzheimer's disease miRNA signatures in a cohort of 54 AD patients and 22 controls from the United States [8] . In a second study using the same technique, we tried to validate the results in a patient cohort collected in Germany that included 49 AD cases, 55 controls and 110 disease controls [10] . The results of both studies were largely consistent with a correlation between both studies of 0.93 (95% confidence interval 0.89-0.96; p<10 -16 ).
Although deep-sequencing applications are increasingly introduced into clinical care, they are mostly performed for the analysis of DNA. RNA profiling, however, is mostly achieved by microarray and RT-qPCR based approaches. In the present study, we provide further evidence that blood-borne miRNA signatures that can be measured by standard RT-qPCR are valuable tools for the minimally-invasive detection of AD. From our above-mentioned studies, we selected a set of 21 miRNAs and determined the abundance of these miRNAs in the blood of 465 individuals. These were subsequently analyzed by biostatistical-, machine-and deeplearning methods.
Methods
Overview on the study: In the current study we included patients from the US [8] and
Germany [10] that were partially collected within the longitudinal TREND study. according to manufacturer's instructions. RNA quantity and quality were assessed using Nanodrop (ThermoFisherScientific) and RNA Nano 6000 Bioanalyzer Kit (Agilent Technologies, Santa Clara, CA, USA). Mean RIN value of the RNA samples was 7.5 (STDEV
1.4).
RT-qPCR: Quantification of miRNAs was performed using miScript PCR system and custom miRNA PCR arrays (all reagents from Qiagen, Hilden, Germany). Custom miRNA PCR arrays were designed in 96-well plates to measure the expression of 21 human miRNAs and RNU48
as endogenous control in duplicates. Two process controls (miR-TC for RT efficiency, PPC for PCR efficiency) were included as single probes. A total of 100 ng total RNA was used as input for reverse transcription reaction using miScriptRT-II kit according to manufacturer's recommendations in 20µl total volume. Subsequently, 1ng cDNA was used per PCR reaction.
PCR reactions with a total volume of 20µl were setup automatically using the miScript SYBR Green PCR system in a Qiagility pipetting robot (Qiagen, Hilden, Germany) according to manufacturer's instructions. Data from samples that failed the quality criteria for the process controls was excluded, leaving expression data from 465 samples available for analysis. For process control over the course of the project, eleven technical replicates of one cDNA sample were measured throughout the course of the project to estimate technical reproducibility. We computed 55 pair-wise correlation coefficients between any pair of the replicates and found a median correlation of 0.996, indicating high technical reproducibility of our assay. Machines or Neural Networks (data not shown).
Data availability
The data is available as Supplemental Table 1 .
Results miRNAs in Alzheimer's disease & Neurodegeneration
In total, 465 participants have been analyzed by RT-qPCR. The abundance levels of 18 of the 21 miRNAs were significantly different between the four groups considered, i.e. AD, MCI, OND, and HC. With an adjusted p-value of 4.8x10 -30 , the most significant miRNA was miR-532-5p, which showed markedly increased levels in AD patients, and slightly increased levels in patients with OND and MCI ( Figure 1A ). The abundance levels of miR-17-3p, the miRNA with the second lowest p-value (p=8.8x10 -28 ), showed a similar pattern as miR-532-5p (Pearson correlation coefficient >0.9). The overall correlation matrix between the 21 miRNAs showed three large clusters of miRNAs with similar expression in the following referred to as Clusters A, B, and C ( Figure 1B) . The third and fourth most significant miRNAs in ANOVA, i.e. miR103a-3p and miR-107 (p=2.4x10 -18 and p=3.6x10 -15 , respectively), came from Cluster C, like miR-532-5p and miR-17-3p. MiR-1468-5p (Cluster A, p=6.2x10 -12 ; Figure 1C ) shows an opposite expression pattern, i.e. a lower abundance in AD patients as compared to HC. The boxplots in Figure 1A /1C also underline that the deregulation of these miRNAs is strongest in AD compared to the HC. There is, however, a deregulation in MCI or OND, but to a lesser extent, such that the altered abundance is at least partially specific for AD. This result is consistent with our previous work based on high-throughput sequencing.
For a more detailed understanding of the miRNAs and their correlation to AD and other factors, we next assessed whether the abundance levels were correlated to age or gender, or, in case of AD and MCI with the MMSE results ( Table 2 ). As Table 2 highlights, none of the miRNAs was associated with gender and five miRNAs were weakly associated with age of patients.
Following adjustment for multiple testing, 14 miRNAs showed a significant differential expression in AD patients compared to controls (i.e. HC, MCI and OND combined). The above mentioned miR-532-5p and miR-17-3p were again the most significant markers for AD.
Furthermore, ten miRNAs were significantly correlated with the MMSE value. Interestingly, all three miRNAs of Cluster B (Figure 1B) , i.e. miR-26a, 26b-5p and let-7f-5p, showed the highest significance for the correlation to MMSE (p < 0.005). Table 2 Comparison between US and German cohorts
It is essential to understand whether biomarkers can be concordantly determined in different cohorts, at best with different ethnicity. We thus compared the profiles measured from German and US patients. As the German cohort was about twice as large as the US cohort and p-values depend on the number of individuals in each cohort, a comparison based only on p-values is potentially biased. Therefore, we computed the fold changes (on a logarithmic scale) between AD and controls ( Figure 2 ). In this plot miRNAs in the upper right quadrant are up-regulated and miRNAs in the lower left quadrant are downregulated in AD compared to controls concordantly in both cohorts. Of 21 miRNAs, only miR-4482-3p was upregulated in the German, but down-regulated in the US cohort. The differences in abundance levels of this miRNA in AD compared to controls were, however, not significant, neither in the German nor in the US cohort, nor in the combined analysis. Thus, miR-4482-3p likely represents a single false positive marker from the initial deep-sequencing based miRNA discovery study. In contrast, the results for the remaining 20 miRNAs were concordant between the US and the German cohort. Furthermore, eleven of these miRNAs were nominally significant in both cohorts, when analyzing the US cohort and the German cohort separately, and remained significant in the combined analysis. These significant miRNAs include miR-103a-3p, miR-107, miR-1285-5p, miR-139-5p, miR-1468-5p, miR-17-3p, miR-28-3p, miR-361-5p, miR-5006-3p, miR-5010-3p, miR-532-5p.
Diagnosis using Machine Learning
To obtain more accurate diagnostic results, molecular markers can be considered as "weak learners" that can be combined by machine learning approaches. For our present data set, we ( Figure 3A ). For the second and more complex case, an AUC of 83.5% was reached ( Figure   3B ). A further advantage of the gradient boosted tree models is that sensitivity and specificity can be well balanced and traded-off. Depending on whether a diagnosis trimmed for sensitivity or for specificity is required e.g. in screening tests, as confirmatory tests or tests for enrollment for clinical studies, a sensitive or a specific model can be chosen.
Function and relevance of miRNAs
To get insights into the targeting of the dysregulated miRNAs, we performed a miRNA Enrichment analysis [11] . Following adjustment for multiple testing, we identified three categories to be significantly enriched including "Dys-regulation in AD" (p=4.8x10 -8 ), "Upregulation in AD" (p=0.00018) and "Age" (p=0.02). Two of three categories were directly related to AD, as to be expected for miRNAs that were known to be associated with AD. In addition, these miRNAs are negatively correlated with age. Although this was a weak correlation, it still suggests that the abundances of these miRNAs are lower in older patients. In contrast, these miRNAs are mostly up-regulated in AD. Performing an enrichment analysis for each of the three miRNAs clusters indicated in Figure 1B , we found cluster A to be especially enriched with miRNAs that are "up-regulated in AD" (p=4.9x10 -6 ) while for cluster B the only significant category was "down-regulated in AD" (p=0.04).
For most miRNAs in our signature, target genes that have been experimentally validated are known. A target network analysis highlighted a very dense network. This network was significantly enriched for genes associated with AD including ABCA1, DAPK1, IGF1R, and VEGFA according to the national institute of aging (NIA). The strongest enrichment was discovered for "DNA damage response" represented by CCND1, CCNE1, CCNE2, CDK6, MYC, RAD51 and RB1.
Discussion
In the current study we present results of our ongoing efforts to develop a diagnostic test for AD patients based on circulating miRNA profiles extracted from blood cells. The current outcomes are consistent with our previous studies in the US and Germany on smaller cohorts.
In contrast to the previous studies relying on deep sequencing, we here applied RT-qPCR as molecular profiling technique that can be more easily driven towards application in clinical care. In the context of the known variability and the bias introduced by sample integrity and sample treatment [12] [13] [14] in deep sequencing data, RT-qPCR offers a promising alternative for routine application. But also for RT-qPCR experiments, there is a debate whether RNA samples with low integrity, i.e. low RIN values, compromise miRNA expression data [15, 16] . In our study, we also measured RIN as quality criterion for RNA integrity of the samples.
The results of the two cohorts from the US and from Germany were highly concordant. As to be expected by the selection of AD-associated miRNAs for this study, the miRNAs and the target genes of the miRNAs were both significantly associated with the development of AD.
Our test that is highly reproducible can be applied with a model based on specificity, sensitivity or trimmed for overall performance. The quality of the results is indicated by an AUC of 87.6%
for the comparison between AD and unaffected controls, and an AUC of 83.5% for a comparison between AD and a combined group of unaffected controls, MCI patients and patients with other neurological disorders. In that, the performance of our diagnostic solution compares well to recently developed other tests such as the plasma amyloid marker introduced by Nakamura and co-workers [4] . While already such single "omics" tests have a large potential, the targeted combination of few representatives from different "omics" classes can add even more diagnostic information, supporting clinicians in detecting AD patients in time.
As for other "-omics" types, confounders including age and gender potentially influence also the results of miRNA biomarker studies [17] . To minimize the influence of such confounders, our cohorts largely show similar age and gender distribution (Table 1 ). In addition, we investigated the influence of the age and gender on the miRNA profiles. Except for a very modest influence of age, we found no evidence for an influence of these confounders on the miRNA pattern. Notably, miRNAs that are up-regulated in AD were partially expected to be lower expressed with increasing age in a normal population.
Among the many different candidates for minimally-invasive and potentially early stage tests for AD, our study indicates that circulating miRNAs likely in combination with other bloodborn "OMICS" profiles will contribute to stable tests applicable to specific diagnostic questions with regard to this highly complex disease. Fold change USA Fold change Germany
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